Catheterization and Cardiovascular Interventions (CCI) Journal Publishes Sahajanand Medical Technologies PAINT Trial 1 Year Results
Summary
Ltd.: By Email RSS Feeds: Catheterization and Cardiovascular Interventions (CCI) Journal Publishes Sahajanand Medical Technologies PAINT Trial 1 Year Results The 74th issue of prestigious international journal Catheterization and Cardiovascular Interventions published an article of Sahajanand Medical Technologies PAINT (PercutAneous INTervention) Trial - A randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (Paclitaxel or Sirolimus) compared against Bare stents: 1-year result. Surat, India, November 01, 2009 --( The article, authored by Dr. Pedro A. Lemos, MD, PhD at Dr. Eneas de Carvalho Aguiar, Sao Paulo Brazil, describes the positive results from the 1-year follow-up of a multicenter, 274 patients (Sirolimus=106, Paclitaxel=111, Bare Metal Stent=57), Phase IV study headed by Dr. Pedro A. Lemos himself.We are happy that we have contributed positively to the interventional community.” The Founder and Chairman of SMT Mr. Dhirajlal Kotadia said, “Sahajanand Medical Technologies always stand in front to support this and other large clinical trials that present the medical community with important scientific data that can be used to provide optimal treatment approach for complex patient subset.” About PAINT Trial: PAINT study was a unique 3-arm format designed with following two objectives, 1) To test two novel drug-eluting stents (DES) covered with a biodegradable-polymer carrier and releasing Paclitaxel or Sirolimus, which were compared against a Bare metal stent.### Surat, India, November 01, 2009 --( PR.com )-- Sahajanand Medical Technologies, a leading developer and manufacturer of Drug Eluting Stents, announced that the Journal of the WILEY inter science - Catheterization and Cardiovascular Interventions (CCI) has published 1 year results from the PAINT trial (ClinicalTrails.gov ID: NCT00752362).We are happy that we have contributed positively to the interventional community.”The Founder and Chairman of SMT Mr. Dhirajlal Kotadia said, “Sahajanand Medical Technologies always stand in front to support this and other large clinical trials that present the medical community with important scientific data that can be used to provide optimal treatment approach for complex patient subset.”About PAINT Trial:PAINT study was a unique 3-arm format designed with following two objectives,1) To test two novel drug-eluting stents (DES) covered with a biodegradable-polymer carrier and releasing Paclitaxel or Sirolimus, which were compared against a Bare metal stent.2) DES differed by the drugs, but was identical otherwise, allowing comparing the anti-restenosis effects of Sirolimus versus Paclitaxel.Angiographic follow-up was obtained at 9 months and major cardiac adverse events up to 12 months.About CCI Journal:Catheterization and Cardiovascular Interventions is an international journal and an official publication of the society for cardiac angiography & interventions.Articles are subject to double-blind peer review and complete editorial evaluation prior to any decision regarding acceptability.About Sahajanand Medical Technologies:Established in the year 1998, SMTPL became the first Indigenous Stent Manufacturer in world to have two DES systems in its product portfolio.